FDA Pharmacy Compounding Advisory Committee Peptide Meeting Two Days Out — Written-Comment Docket FDA-2025-N-6895 Closes at 11:59 PM ET Wednesday July 22, With the Thursday-Friday July 23-24 Vote Opening at 8:00 AM ET Thursday and Closing at 3:50 PM ET Friday at FDA White Oak Campus in Silver Spring, Maryland: Day 1 (Thursday) Reviews BPC-157, KPV, TB-500, and MOTS-c; Day 2 (Friday) Reviews Emideltide (DSIP), Semax, and Epitalon; The Washington Post Reports on July 17 That FDA Career Staff Raised Conflict-of-Interest Concerns Ahead of the New Peptide Panel
The FDA Pharmacy Compounding Advisory Committee (PCAC) peptide meeting is two days out. Written-comment docket FDA-2025-N-6895 closes at 11:59 PM ET on Wednesday July 22, 2026 (comments received via the Regulations.gov electronic filing system after that time will not be considered). The two-day meeting opens Thursday July 23 at 8:00 AM ET and closes Friday July 24 at 3:50 PM ET at FDA's White Oak Campus in Silver Spring, Maryland. Day 1 (Thursday) reviews BPC-157, KPV, TB-500, and MOTS-c for 503A bulks-list eligibility. Day 2 (Friday) reviews DSIP (Emideltide), Semax, and Epitalon. The Washington Post reported on July 17 that FDA career staff had raised conflict-of-interest concerns ahead of the new panel composition, adding to the June 29 STAT News reporting that seven of eight new PCAC members named have documented ties to peptide-related businesses. FDA career-staff briefing documents released June 29-30 recommended against adding any of the seven peptides to the 503A Bulks List. The American Pharmacists Association (APhA) filed docket comments this month urging the FDA to put patient safety first in the review.